

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

APPENDIX 5
FORMS RELATING TO LISTING
FORM F
GEM
COMPANY INFORMATION SHEET

Case Number: Not applicable

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name: China Regenerative Medicine International Limited

Stock code (ordinary shares): 8158

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on GEM of The Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 18 December 2023

A. General

Place of incorporation: Cayman Islands

Date of initial listing on GEM: 18 July 2001

Name of Sponsor(s): N/A

Names of directors:
*(please distinguish the status of the directors
- Executive, Non-Executive or Independent
Non-Executive)*

Executive Director
Mr. Wang Chuang (Chairman and Chief Executive Officer)

Non-Executive Director
Mr. Tsang Ho Yin

Independent non-executive Directors
Ms. Huo Chunyu
Dr. Liu Ming
Mr. Leung Man Fai

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

- Name(s) of substantial shareholder(s):
(as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company
1. Wang Chuang is interested in 73,875,530 shares of the Company, representing approximately 24.28% of the issued share capital of the Company;
 2. Mr. Li Ren ("Mr. Li") personally owns 2,138,000 shares of the Company. Mr. Li is therefore deemed to be interested in an aggregate of 60,392,776 shares of the Company, representing, approximately 19.85% of the issued share capital of the Company.
 3. All Favour Holdings Limited is interested in 58,254,776 shares of the Company, representing: approximately 19.15% of the issued share capital of the Company (Note 1).

Note 1:

All Favour Holdings Limited ("All Favour") is beneficially owned as to (i) 40% by Nat-Ace Wood Industry Ltd. ("Nat-Ace Wood Industry") and 20% by Honour Top Holdings Limited, of which Nat-Ace Wood Industry is ultimately and wholly-owned by Mr. Li and Honour Top Holdings Limited is ultimately wholly owned by Mr. Dai Yumin ("Mr. Dai"), and (ii) 40% by Mr. Dai. Moreover, All Favour has been the beneficial owner of 58,254,776 shares of the Company. By virtue of the SFO, Mr. Dai, Mr. Li and Nat-Ace Wood Industry are deemed to be interested in 58,254,776 shares of the Company in which All Favour is interested in.

On 31 March 2022, a bankruptcy order was made against Mr. Dai. Subsequently, Messrs. Arab Osman Mohammed and Mr. Wong Kwok Keung were appointed as joint and several trustees (the "Trustees") of the property of Mr. Dai at the general meeting of creditors held on 6 May 2022. Accordingly, the property of Mr. Dai, including his shareholdings, shall vest in the Trustees pursuant to section 58(2) of the Bankruptcy Ordinance (Cap. 6).

- Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company: Not applicable
-
- Financial year end date: 31 December
-
- Registered address: Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands
-
- Head office and principal place of business: Suite 2310-2318, Miramar Tower, 132 Nathan Road, Tsim Sha Tsui, Hong Kong
-
- Web-site address (if applicable): www.crimi.hk
-

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Share registrar: Principal Share Registrar
Conyers Trust Company (Cayman) Limited
Cricket Square, Hutchins Drive
P.O. Box 2681
Grand Cayman, KY1-1111
Cayman Islands

Hong Kong Branch Share Registrar
Union Registrars Limited
Suites 3301-04, 33/F,
Two Chinachem Exchange Square, 338 King's Road
North Point Hong Kong

Auditors: McM (HK) CPA Limited
Room 2402, 24/F,
Siu On Centre,
188 Lockhart Road,
Wanchai, Hong Kong

B. Business activities

The Company is an investment holding company and the principal activities of its subsidiary are provision of medical beauty services and healthcare products.

C. Ordinary shares

Number of ordinary shares in issue: 304,252,480

Par value of ordinary shares in issue: HKD 0.20 per share

Board lot size (in number of shares): 5,000 shares per lot size

Name of other stock exchange(s) on which ordinary shares are also listed: Not applicable

D. Warrants

Stock code: Not applicable

Board lot size: Not applicable

Expiry date: Not applicable

Exercise price: Not applicable

Conversion ratio: Not applicable
(Not applicable if the warrant is denominated in dollar value of conversion right)

No. of warrants outstanding: Not applicable

No. of shares falling to be issued upon the exercise of outstanding warrants: Not applicable

E. Other securities

Details of any other securities in issue.
(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

THE STOCK EXCHANGE OF HONG KONG LIMITED
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

(A) References are made to the announcement of the Company dated 16 September 2015 regarding the option grant (the “2015 Grant”) and the announcement of the Company dated 4 September 2023 regarding the adjustment to the number and exercise price of the outstanding share options. Further information of the Options are as follows:

Date of Grant: 16 September 2015

Option Period: 16 September 2015 - 15 September 2025 (both days inclusive)

Adjusted Exercise Price: HK\$90.00 per share No. of new shares which may be issued upon the exercise of Options under the 2015 Grant as at the date hereof: 330,200 ordinary shares of the Company

(B) References are made to the announcement of the Company dated 9 September 2016 regarding the option grant (the “2016 Grant”) and the announcement of the Company dated 4 September 2023 regarding the adjustment to the number and exercise price of the outstanding share options. Further information of the Options are as follows:

Date of Grant: 9 September 2016

Option Period: 9 September 2016 - 8 September 2025 (both days inclusive)

Adjusted Exercise Price: HK\$58.2 per share

No. of new shares which may be issued upon the exercise of Options under the 2016 Grant as at the date hereof: 390,520 ordinary shares of the Company

Responsibility statement

The directors of the Company (the “Directors”) as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet (“the Information”) and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Submitted by: Khoo Wun Fat William
(Name)

Title: Company Secretary
(Director, secretary or other duly authorised officer)

NOTE

Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the GEM website a revised information sheet as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.